Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis

Osteoporosis International

Volumn 12, Issue SUPPL. 3, 2001, Pages

  Miller, P D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID;

ALCOHOL CONSUMPTION; ASTHMA; BODY MASS; BONE DENSITY; BONE MASS; CHRONIC LUNG DISEASE; CIGARETTE SMOKING; DISEASE ASSOCIATION; DRUG TOLERABILITY; FRACTURE; HUMAN; LONG TERM CARE; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK FACTOR; TEMPORAL ARTERITIS; TREATMENT PLANNING;

EID: 0035703428     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014038     Document Type: Review

References (39)

1. Bone loss in response to long-term glucocorticoid therapy
2. Rheumatoid arthritis, corticosteroid therapy and hip fracture
3. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men
4. Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study
5. Bone loss and turnover after cardiac transplantation
6. Progression of steroid-associated osteoporosis after heart transplantation
7. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
8. New developments in biochemical markers for osteoporosis
9. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study
10. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update
11. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
12. Risedronate therapy prevents corticosteroid-induced bone loss
13. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids
14. Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of osteoblast-like cell proliferation
15. Cortisol decreases IGF-1 mRNA levels in human osteoblast-like cells
16. The science and therapy of glucocorticoid-induced bone loss
17. The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated by cells of the osteoblastic lineage
18. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts
19. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
20. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
21. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo
22. Bone densitometry: The best way to detect osteoporosis and to monitor therapy
23. The challenges of peripheral bone density testing
24. Clinical application of bone densitometry: Primer on the metabolic bone diseases and disorders of mineral metabolism
25. Discordance in patient classification using T-scores
26. Biochemical markers of bone turnover for the clinical assessment of bone metabolism
27. Prevention of glucocorticoid-induced osteoporosis
28. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel
29. Predicting bone lose and fracture risk with biochemical markers: A review
30. Basic principles and clinical applications of biochemical markers of bone metabolism: Biochemical and technical aspects
31. Antifracture efficacy of antiresorptive agents is related to changes in bone density
32. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
33. Two-year follow-up of bisphosphonate (ADP) treatment in steroid osteoporosis
34. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
35. Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids
36. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
37. Prevention of bone loss after heart transplantation with antiresorptive therapy: A pilot study
38. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis